Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 study of glucodynamic effects of dulaglutide in Japanese patients with type 2 diabetes mellitus
jRCT1080223698Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of dulaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Started Oct 2017; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1080223698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223698.